Medscape March 12, 2025
ORLANDO, Fla. — First deployed in the United Kingdom’s National Health Service (NHS) in 2020, an artificial intelligence (AI)-based evaluation of dermatoscope images was found in a real-world performance review to at least match, if not exceed, that of expert reviewers.
Conducted at 15 participating hospitals, the performance review demonstrated that this AI tool allowed patients without cancer to be “safely discharged, thereby releasing dermatologists to focus on patients who actually have skin cancer,” reported Dilraj Kalsi, MBBS, a researcher at Skin Analytics, the London-based company that developed the AI tool as a medical device (AIaMD).
The name of the proprietary AIaMD is DERM (Deep Ensemble for the Recognition of Malignancy) and is now in routine use at 19 centers...
Today's Sponsors
Today's Sponsor